List view / Grid view
Using GenAI and expert reasoning, drug developers can now explore an asset’s long-term potential as early as the preclinical stage. This shift is helping to reshape pipeline planning and refine therapeutic strategy.
AI is changing how clinical trials are run - quietly but significantly. Find out how digital twins are helping sponsors reduce control arms and accelerate development without changing trial endpoints.
Think drug discovery is slow? This biotech is moving faster, smarter and deeper – by asking the question that no one else has.
Amelie Croset of Molecular Partners breaks down the DARPin developments featured at AACR 2025 – from targeted radiopharmaceuticals to precision-engineered immune cell engagers.
As the lab–data science divide continues, Ian Kerman looks ahead to a future of deeper collaboration – one where shared skills, smarter tools and a shift in mindset could finally break down the barriers. In this second interview, he shares his vision, practical ideas and advice for the next generation…
James Atwood, COO of Opentrons, shares how accessible lab automation is helping research teams tackle tighter budgets, faster timelines and complex discovery workflows.
A practicing surgeon turned biotech CEO is developing a novel pain medicine that could sidestep the failures of both opioids and paracetamol.
President Trump’s proposed drug pricing reforms are putting pressure on early-stage discovery. To keep pace, teams must rethink how they manage risk, resources and collaboration.
Genomics laid the foundation for precision medicine, but on its own, it offers only part of the picture. This article explores how integrated multiomics can provide the deeper biological context needed to drive more effective therapies forwards.
Discover how Domain Therapeutics is using its deep knowledge of GPCR biology to create novel therapeutics with the potential to combat inflammatory diseases such as atopic dermatitis, IBD and arthritis.
What if you could actually see where a drug travels in the body down to the cellular level. Find out how mass spectrometry imaging (MSI) is making that possible – reshaping drug development from the inside out.
Lab scientists and data scientists often speak different languages and that miscommunication can slow down important research. In this interview, Ian Kerman shares how his team is working to break down those walls and spark better collaboration.
What does ethical research look like in drug discovery today? In this interview, Charles River’s Executive Director of Global Animal Welfare shares how global standards, the 3Rs and her own path as a woman in STEM are shaping efforts to reduce animal use in science.
Drug development has long been hindered by fragmented data and complex processes, but a new wave of AI is reshaping the landscape. By integrating genomic, clinical and molecular data, multimodal models are revealing hidden patterns and accelerating more precise advancements in medicine.
Alltrna is redefining the future of rare disease treatment with engineered tRNA therapeutics that target genetic mutations - not just individual diseases. CEO Michelle Werner shares how this bold, mutation-driven approach could unlock universal treatments for thousands of patients long overlooked by traditional medicine.
